treatment
Finally, recent pilot trials have demonstrated that macrolide       antibacterial treatment directed against C. pneumoniae reduces the risk of       recurrent coronary events.
Finally, recent pilot trials have demonstrated that macrolide        @OBJECT$  @PREDICAT$  @SUBJECT$  directed against C. pneumoniae reduces the risk of       recurrent coronary events.